Phase 1/2 Dose-Rising, Safety, Tolerability and Efficacy Study of Topical SOR007 for Cutaneous Metastases

Trial Profile

Phase 1/2 Dose-Rising, Safety, Tolerability and Efficacy Study of Topical SOR007 for Cutaneous Metastases

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Cancer metastases; Skin cancer
  • Focus Adverse reactions
  • Sponsors Dfb Soria; Nanology
  • Most Recent Events

    • 06 Feb 2018 Planned End Date changed from 1 Feb 2019 to 1 Apr 2019.
    • 06 Feb 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2019.
    • 06 Feb 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top